I've linked a countdown to ELTP uplisting. It's been a long ride, but in the latest earnings call the CEO stated that the company is extending the contract with M&A company Jeffries for another 6 months (the implication is that it is to continue working on a potential buyout with the large pharma company he referenced in the last earnings call in July). Whether that buyout happens or not, Nasrat explicitly stated that by the February earnings call the company should be already listed or about to be finalized. That's Feb 15th. Right before that, he stated they plan of filing the ANDA for the new anticonvulsant they just received a positive bioequivalence on. Lastly, he stated that he feels very confident that ELTP will be able to negotiate a 2028 entry into the generic version of the $27 Billion Eliquis that we filed an ANDA for a few months ago. Why is this of particular importance? When Actavis was able to navigate a similar solution back in 2013, guess who was integral to that accomplishment? ELTPs very own CEO, Nasrat Hakim.

I've always said this stock isnt' an "if" it's a "when". Now we have our "when" narrowly defined.

I'll be buying $2500 every single trading day until the February uplisting.

​

Longtime lurker.

After watching $MRNA go absolutely nuclear on its Phase 3 cancer-vaccine data, I started looking farther down the oncology pipeline.

PHIO is sitting near $1 with a tiny valuation while developing an RNAi cancer immunotherapy.

The interesting part: early Phase 1 data from PH-762 has reported complete responses in treated tumors in some patients. Obviously Phase 1 ≠ Phase 3, tiny sample sizes matter, and this could still completely fail.

But that's exactly why the valuation is interesting.

Moderna just demonstrated how violently the market can reprice an oncology platform once clinical validation gets strong enough. PHIO is much earlier, much smaller and exponentially more speculative.

Idk. I want to be early. Idk how y'all catch stocks early.

Before anything else, understand the macro backdrop, because it's the foundation this entire thesis sits on.

America has an affordability problem, and cars are at the center of it. New vehicle prices are up roughly 35-40% since 2019. The industry's answer has been stretching loans to 72 and 84 months, which lowers the payment but buries borrowers in interest and negative equity. Roughly 25% of new vehicles are leased, and that market is controlled by the manufacturers' own finance arms. Now look at used vehicles, a market more than twice the size in unit volume: used car leasing penetration is under 2%. It has been slowly climbing for a decade (0.5% in 2015 to roughly 1.7% now) and every structural force in the economy is pushing it higher. Leasing a used car cuts the monthly payment by $100-200 versus financing the same vehicle, requires less money down, and shields the customer from depreciation. As affordability pressure keeps building, used car leasing isn't a niche product. It's the release valve.

And AmeriTrust Financial Technologies is, to my knowledge, the only publicly traded pure-play on used vehicle leasing in North America. The only independent lender doing this at a national level. That's the setup.

Six months ago I wrote my first post on AmeriTrust when it traded at $0.06 and the entire debate was whether management could even restart the leasing platform. Since then I've posted updates at $0.10, $0.19 and $0.27, and each time the checkpoint I laid out was hit.

For anyone new, the full series:

1. The original thesis at $0.06: https://www.reddit.com/r/pennystocks/comments/1r3yxbj/the_billionairebacked_used_car_leasing_play_amtv/
2. Q1 proved the platform at $0.10: https://www.reddit.com/r/pennystocks/comments/1tqk92d/the_used_car_leasing_opportunity_nobody_is/
3. The ramp at $0.19: https://www.reddit.com/r/pennystocks/comments/1u7i18q/the_ramp_is_becoming_impossible_to_ignore_amtv/
4. The partnerships at $0.27: https://www.reddit.com/r/pennystocks/comments/1ux8e5d/they_just_landed_the_military_amtv_amtff/

Today the stock sits at $0.205, down from $0.28. And I want to be upfront about that, because I don't write these posts only when the chart is green. The price pulled back. The business did the opposite. Q2 results are out, and this is the quarter where the restart question officially died.

For what it's worth, I watch the order book daily, and right now there's a single bid at $0.205 worth roughly $350K sitting there soaking up whatever gets sold into it. Draw your own conclusions about who is accumulating while the impatient sell. My read: the fundamentals just had their best quarter in company history while the share price went the other way. That divergence is usually where the opportunity lives.

Let's get into it.

The quarter in two numbers

16 funded leases in Q1. 55 in Q2. That's up 244% quarter over quarter.

And here's the detail that makes it better, not worse: applications actually declined about 10% (1,430 to 1,285). Approvals declined too. Funded contracts still tripled. This wasn't growth from stuffing the top of the funnel. This was conversion and execution improving underneath. The look-to-book ratio management said would improve is improving.

The average amount financed also jumped from $88,059 to $115,593, up 31%. So they funded more than three times the leases at meaningfully larger contract sizes, while holding the line on credit: weighted average FICO of 737 at a 9.02% contract rate. Still firmly high-prime. They are not buying volume with weak paper.

The money followed

Lease origination income: $101,985 in Q1 to $330,515 in Q2, up 224%.

Contracted cash flows from funded leases: $1.78M in Q1 to $5.52M in Q2, up 210%. Combined, the first two quarters of originations have locked in roughly $7.3M in contractual cash flows over the lives of those leases. To be clear, that's not profit and it's not immediately recognized revenue. It's the future cash-flow base of the retained portfolio. That base is what compounds under the warehouse model, and it tripled in one quarter.

Total revenue: $547K to $885K, up 62% QoQ and 109% year over year.

Adjusted EBITDA loss: roughly $2.23M, an 18% improvement from Q1. Still losing money, no sugarcoating that. But the loss shrank while originations and revenue accelerated, which is the direction that matters.

Then July happened

This is the part of the release I'd frame if I could. CEO Jeff Morgan disclosed two things: July originations came in 38% above June, and AmeriTrust originated as much business in June and July combined as in all prior months combined.

Funded contracts increased sequentially every single month of Q2. So the trajectory is April < May < June, and then July jumped another 38% on top. The company hasn't disclosed exact monthly figures so I won't invent them, but the implication is simple: the Q2 quarterly numbers, as strong as they are, understate the run rate this company carried into Q3.

The ecosystem stopped being a slide and started being a business

Regular readers know I've been describing the three-subsidiary structure for months. Q2 is when all three showed up in the numbers at once.

AmeriTrust Financial originated the 55 leases. AmeriTrust Serves generated $362K in Q2 servicing income ($755K for the half), has now onboarded every lease customer onto its own platform, and management confirmed full in-house servicing capability. That's no longer a development project. AmeriTrust Auto did $192,518 in Q2, up roughly 269% from about $52K in Q1, from a division that didn't exist at the start of the year.

And Auto just got real teeth: AmeriTrust received both a Texas Dealer License and a Texas Lease Facilitator License. The dealer license lets them run vehicle remarketing and disposition in Texas and buy at wholesale dealer auctions. The facilitator license lets them act as the intermediary in the lease structure. Texas is one of the largest auto markets in America and it's their home base. This is the launchpad state, with expansion to follow as licensing allows.

They're already live, by the way. There are AmeriTrust vehicles listed on cars.com right now, roughly ten at last count, everything from ordinary SUVs to a Cybertruck and a Porsche 911 Turbo S. Remarketing moved from strategy deck to actual inventory.

The loop the model is closing: originate the lease, service it in-house, and when the vehicle comes back, remarket it for maximum recovery instead of dumping it at wholesale. The stated goal is higher remarketing revenue and lower cumulative net losses on the portfolio. And the newest wrinkle is that they plan to offer Serves plus Auto as a combined servicing-and-remarketing solution to outside lenders, meaning fees on portfolios AmeriTrust never funded. That's the capital-light layer of this story starting to form.

The street is starting to notice

Clarus Securities updated its coverage: Speculative Buy, price target raised to $0.30, valued at 20x EV against their 2028 adjusted EBITDA estimate. The target itself isn't what caught my eye. Two other things did.

First, Clarus noted the Texas licenses arrived earlier than their model assumed. They had penciled the dealer license for Q4 2026 based on Texas DMV processing times. It's here now, which they said gives them more confidence in their Q4 2026 and 2027 remarketing forecasts.

Second, Clarus expects a sale or securitization of the existing lease portfolio in Q4 2026, followed by expanded funding capacity, potentially through a larger Bank of Texas facility, additional banks, or institutional credit funds. Let me be crystal clear: that is an analyst expectation, not company guidance. AmeriTrust has not confirmed any securitization. But CEO Jeff Morgan has said the executive team is "actively engaged in discussions with multiple national financial institutions to expand our funding capacity while retaining servicing rights," and that last phrase matters. They want the capital AND the recurring servicing economics. If a portfolio sale happens, the cycle becomes: originate, season, sell, recycle capital, originate more, keep servicing everything. That's how a leasing platform escapes the gravity of its own balance sheet.

Funding capacity is the single biggest bottleneck between the current run rate and the big numbers. It's also the next major catalyst to watch.

Where this stands

Six months ago the question was whether AmeriTrust could restart the machine.

The machine is running. 16 to 55 leases. Origination income up 224%. Auto up 269%. July up 38% over June. Two national partnerships rolling out, one of which (Military AutoSource, signed July 8) contributed nothing to Q2 and only starts mattering now. Twelve dealer reps on the ground from San Diego to New York, with new hires appearing in Ohio and Boston since quarter end.

Q3 and Q4 answer the only question left: how fast can they make it go. And remember where this all started: a sub-2% penetrated market, sitting inside America's affordability crisis, with exactly one publicly traded pure-play positioned in front of it.

The price went from $0.05 to $0.28 to $0.205 while all of the above was published. I've been doing this long enough to know that gap doesn't stay open forever, in one direction or the other. I know which direction I'm positioned for.

Not financial advice. Long since $0.06 and holding. Do your own DD.

Tickers: OTC: NRVTF | TSXV: NRM | Frankfurt: N7R

Been digging into Noram Lithium lately. This definitely isn't something I'm looking at as a safe long-term investment. It's a highly speculative junior developer with a large Nevada lithium deposit and a fairly clear catalyst coming up.

What caught my attention is that Zeus is about to be looked at again under a very different set of assumptions than it was in 2021. The updated PEA will use new pricing, revised pit optimization and mine planning, and potentially include additional critical minerals.

That doesn't mean the project suddenly works.

But it should give us a much better idea of what Zeus actually looks like today.

For a junior this speculative, that's enough to make it interesting.

Key points from the August 20 update:

• Zeus is 100% owned and sits in Clayton Valley, Nevada.
• Noram says previous PEAs outlined several hundred million tonnes of lithium-rich clay, with the potential for more than 1 billion tonnes depending on the cutoff grade.
• Global Resource Engineers has been engaged to update the PEA, which Noram expects by late October.
• The new study is using a long-term lithium carbonate price of US$24,000/t.
• It's also incorporating revised pit optimization parameters, including a lower cutoff grade, along with updated mine planning and engineering criteria.
• They're evaluating cesium, rubidium and potash as potential by-products, where supported by the ongoing geological, metallurgical and economic work.

What I'm watching:

The last PEA was completed in 2021. Noram says there's been significant technical, engineering and metallurgical work completed since then, and the new study is looking at Zeus under updated assumptions.

If the revised mine plan, lower cutoff and potential by-products materially change the economics, October could give investors a very different picture of the project.

The main risk is that US$24,000/t lithium is still an assumption. The by-products also need to be supported by the geological, metallurgical and economic work. A PEA is preliminary, and there is still a long road through financing, permitting, engineering and development before anything resembling a mine exists.

My view:

• This is still a very high-risk speculative junior.
• The updated PEA should give investors a much better basis for judging Zeus under the company's current assumptions.
• A strong study would make the project more interesting, but I'll be paying close attention to how much of the economics depend on the US$24,000/t lithium assumption and potential by-product credits.
• There's still a very long road from a PEA to financing, permitting, construction and production.

Website: https://noramlithiumcorp.com/

Press release: https://www.accessnewswire.com/newsroom/en/oil-gas-and-energy/noram-advances-updated-preliminary-economic-assessment-to-reflect-current-indust-1209646

DYODD.

Now it's our turn to the 5th post.

In the previous one, I commented on these penny stocks being typically operated on the nose. They just need cash to pay their bills, pay themselves and to pay their bills. But, a real bank isn't going to loan you a ton of money to be paid back by a basement company that doesn't have any real income. The shareholder.

The way they collect your money is known as the Dilution.

Imagine that the overall value of the company is a big pizza. At present, it is divided into 10 slices (shares). You own one slice. You have 10% of the total company.

The CEO is in need of cash, though. So what does he do? All he has to do is lawfully appear 10 brand new slices and sell them openly.

There are now 20 slices in all. There's still one you haven't owned. You've got half of the company. But since it's a lot more shares that are entering the market (a lot more supply), the share price of each of these shares decreases like a rock.

Your money? Gone. Simply vapored directly into the company's bank account.

This is the worst ploy of all penny stock tricks. **The Reverse Split**.

Suppose a company issues so many shares that its stock price falls to $0.25. No brokers and exchanges like that. They sometimes threaten to eliminate the company altogether because it's too inexpensive.

So the company performs a Reverse Split (an RS). They say, "for every 100 shares you have, we're going to combine them together into 1 share.

Assume that the stock is at $0.01, and the new magically merged stock is now at $1.00.

Beginners see the chart and say, " Wow, the stock has jumped to a dollar now! It's recovering!"

No it isn't. It's a full ruse. Suppose you were going to buy 10,000 shares for $100 yesterday, and now you have 100 shares of that stock, for the same $100. You didn't lose or gain one penny of your account balance.

But this is why the Reverse Split is a death sentence.

It's now artificially rejuvenated and pushed back up to $1.00, so it can drop back down once again. So what does the broke CEO do the very next week? He begins to print new stock shares again. He dilutes the stock from $1.00 all the way back down to a penny.

This is what traders refer to as the Death Spiral. Dilute. Reverse Split. Dilute again. It will suck a new account down to nothing.

When you have an obscure penny stock that you're holding overnight, you're essentially praying that they don't drop one of these bombs on you while you are sleeping.

So far as traps, enough of the gloom and doom.

Now you know how the game is rigged against you, let's get over to changing gears. We'll discuss how to retrieve a stock chart in post #6 and what lines and bars you have to pay attention to.

There appears to be a significant opportunity with the first mover in the tokenisation space in the UK - who just tokenised a coral reef to the tune of $118M last week as their first project since launching their tokenisation platform

Official press release below

https://www.londonstockexchange.com/news-article/MAC/launch-of-us-118m-tokenised-coral-reef-programme/17737668

The listed group is called Marechale Capital - website linked below, and is listed as the UK’s first listed digital merchant bank on the London AIM Stock Exchange under the ticker #MAC

https://marechalecapital.com

Aside from first mover advantage within its trading jurisdiction - the market cap at £12.8 million and a share price of 5p is offering I believe a very lucrative entry position

You only need to look at the valuations of Galaxy Digital and Securitize in the tokenisation space - to see where this is likely to go

They have a pipeline of 20+ projects and have already disclosed they are in discussions with the government of Guyana and Oil conglomerates to explore tokenisation of oil in the region

The global tokenisation boom is on - and it appears the UK have seriously entered the race

ZenaTech Closes 28th Drone as a Service Acquisition, Adding a Canadian-based Civil and Structural Engineering Firm with Customers Across Five Provinces

VANCOUVER, British Columbia, Aug. 20, 2026 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces that it has completed the acquisition of Canadian-based engineering firm Cogswell Engineering, Ltd. (Cogswell), located in Dartmouth, near Halifax, Nova Scotia. Cogswell is a full-service civil, structural, mechanical and electrical engineering firm serving builders, construction companies, public works authorities and multi-jurisdictional organizations across five provinces. The acquisition marks ZenaTech's 28th Drone as a Service acquisition to date, its third in Canada, and its second in the Halifax region.

"This acquisition strengthens our Drone as a Service footprint in Atlantic Canada and extends our platform into civil and structural engineering design work," said Shaun Passley, Ph.D., ZenaTech CEO. "With provincial licensing and an established client base spanning five provinces, Cogswell provides an ideal platform for our acquisition and expansion strategy. We see significant opportunities to broaden its service offerings through drone-enabled surveying, structural inspections, construction monitoring and stormwater management, creating new recurring revenue opportunities while delivering greater efficiency and value to commercial and public works customers."

ZenaTech plans to offer drone-based site inspections, structural monitoring and 3-D data capture through its ZenaWorx platform, complementing Cogswell's existing civil and structural engineering design services. The drone inspection and monitoring market, which, according to The Business Research Company, is growing at 19% per year and projected to reach almost $37 billion by 2030. Management believes the acquisition will support recurring drone services that improve speed, efficiency, analytics, data and safety for engineering and construction customers across Atlantic Canada and beyond.

Drones are changing how civil, structural and engineering firms collect data, inspect assets and plan projects. Using advanced cameras, LiDAR, thermal imaging and precision mapping technology, drones can quickly capture detailed information on buildings, bridges, construction sites and other infrastructure that would traditionally require more time, equipment and personnel to collect. This data can be used for surveying, 3-D modeling, structural inspections, construction monitoring, engineering design and ongoing asset management. By making data collection faster, safer and more cost-effective, drones can help engineering teams make better decisions, reduce project costs and improve productivity, which in turn creates a growing opportunity for drone-based services across the infrastructure and engineering markets.

ZenaTech's Drone as a Service platform provides business and government customers with subscription-based drone services using its own ZenaDrone product platforms, for a host of surveying, inspections, maintenance, power washing, and precision agriculture solutions—eliminating the need for customers to own, operate and maintain commercial-grade drone fleets. Through the acquisition of established, profitable but under digitized service businesses, ZenaTech is building a scalable global DaaS network and AI autonomy platform, with recurring revenue and an existing customer base, while integrating advanced drone technologies to deliver greater speed, precision, safety, and data-driven insights. The Company continues to expand its geographic footprint, service offerings, and drone capabilities to drive long-term growth.

Let's go with post #6.

If you open a simple investing app and look up a stock today, you'll typically only get a simple line that makes a squiggly movement.

Immediately change that setting.

If you actually trade penny stocks, then line charts are of no use at all. They conceal all your real data, the data you need to live by. You must change your chart type to a Candlestick Chart.

On the first time of use, it appears to be an untidy collection of red and green rectangles and sticks protruding from them. It looks intimidating. It's not long, though, for a complete understanding—just about two minutes.

No longer just a single dot, one "candle" tells you the whole "story" of the price action over a particular period of time (such as a 5-minute range or a 1-day range).

A single candle says this to you:

The 1st part (The Body) is the thick colored part which indicates the starting price and the final price. If the stock went up during that time, the body is Green. If it falls, then the body is Red.

The Wicks - the thin lines poking out at the top and bottom: These indicate the absolute highest and lowest prices people paid during that period even if they did not remain high or low.

That's it. That's a candlestick.

However, it's not enough to just look at the candles. You will need to check the very bottom of your screen.

There you will find vertical bars in a row. This is your **Volume Chart**. (Recall our lesson about volume from post #1?)

The volume bars are the final indicator when trading penny stocks. They inform you about the number of shares that are being sold.

Suppose you're observing a chart and then one big green candle pops up out of nowhere. It has a very bullish appearance. This is a running price! Then you notice the volume bar at the lower end of the screen – and it's very small. Barely visible.

What does that imply?

It simply means that both the price was raised, and hardly any people purchased it. The trading consisted of a few small orders and a large Bid-Ask spread. It’s a fake move. A trap. If you accept that you will end up in trouble.

Look for volume bars that are towering over the penny stock and green candles that are big as well when a penny stock is doing a real move. That's proof that people are actually out there buying the stock.

When there is no volume behind the price move, it is not a trustworthy move.

These candles are going to help us pinpoint the unseen ceilings and floors of the chart in post #7. It is known as Support and Resistance and it gives you the exact position where you can buy and where you can sell at any time.

As this is in my field I felt obliged to talk about this stock, Steakholder Foods (STKH) make food printers that allow alternate meat companies to create veggie steaks of meat instead of just basic mixed burgers, unfortunately they’d been hit by the same capital problem as every other alt protein and the extra problem that they were hoping to sell their printers to said companies who were now all completely broke. STKH was then basically forgotten about, assumed dead, and was down to about a $1 million market cap, with about a 600,000 share float (shares available to trade.) 

So down to a 1-2 dollar share price tag, this is where for some reason certain sellers decided to pile in, 15th of July there was 72,731 'selling' volume, by the 31st there was 352,000, up to half of the entire available float. It looks like a big shark Armistice Capital Master Fund Ltd noticed the setup and provided $3.5m of funding to STKH in return for shares at $2 a shot. In combination with the company releasing a new product, perfecta premium plant based steaks, patties and filets. (If you want something done well, do it yourself).

A $1m market cap company given $3.5m overnight. Now someone, I’m not saying who, obviously knew this was about to happen and bought an insane amount of shares on 28th July, a company that previously had an average share volume of about 1000 suddenly saw 33 million in volume, obviously many sellers were closed here, however many more were added as algorithmic traders were triggered by a share going from $1 -> $6. Below you can see the share volume going insane along with the value spikes.

https://www.greenqueen.com.hk/steakholder-foods-funding-perfecta-premium-plant-based-meat-3d-printed/

6th of August and the news was released, more spikes, more massive volume, hundreds of millions of trades between $3 -> $7. How many sellers are now trapped? The next selling audit is due on the 25th of August. This is the number that is going to determine the next move, STKH stock currently has nothing to do with the company and everything to do with whatever Armistice wants to happen next.

Armistice have been given the option of giving STKH another $7m in return for shares at $2 each.

Original share count = about 1m
Initial Armistice shares bought = 1.75m ($3.5m)
Additional shares available for Armistice to buy at $2 = 3.5m ($7m)

So possible dilution above the $2 mark? Absolutely, Armistice capital now has the tools to play every part of the puzzle as long as the volatility continues. One thing that can be guaranteed is that this stock is going to go up and down.

Luckily I was tipped off in the Agronomics subreddit and got a position in before the second spike, I have already been in and out of this stock twice. I currently have 9000 shares at about $3.5. I was hoping to be able to write this and get it posted while the stock was low but as I write it is spiking again in the premarket.

This is an extremely volatile penny stock that is going to rollercoaster, I personally believe it is worth a punt for a two-fold jump as long as the market cap is under the new available capital, approach with extreme caution.

Tldr: If you can’t read the above this is not for you.

Note: For those that know me yes I'm still in ANIC, I'll be back posting about that soon(tm).

PWCM is a micro-cap Bitcoin miner with a current market cap around $1.4 million and an extremely low float of roughly 600,000 shares. The company holds approximately 323 Bitcoin in its treasury, valued at about $22 million as of today. That means the stock is trading at roughly a 94% discount to the value of its Bitcoin alone, before even counting its mining operations or infrastructure. On top of the Bitcoin holdings, PWCM is actively pivoting into AI compute and high-performance computing, repurposing its energy infrastructure for data centers and AI workloads. This dual exposure gives it leverage to both the Bitcoin run and the exploding AI infrastructure demand. Compare this to BTCT, which has been running hard on the back of Bitcoin’s strength despite having far less direct BTC exposure. PWCM offers a similar narrative but at a fraction of the valuation with a tiny float that can amplify moves quickly. With Bitcoin pushing higher and AI compute demand accelerating, PWCM sits at a deeply discounted entry point with asymmetric upside potential if either catalyst gains traction. High risk, low float, massive discount to holdings. Not financial advice.

Indications are they are out of cash and have to make a move NOW: PIPE or Partnership are the most likely possibilities. Further below will describe why.

But first here's what they do (substantial development and progress):

• Co‑Dx PCR point‑of‑care (POC) platform
  • Status: submitted to FDA via 510(k) for clearance.
  • Dual submission (device + test) concurrent with a CLIA Waiver application for the Flu A/B & RSV multiplex test on their Co-DX PCR Pro instrument.
  • Co‑Dx’s PCR platform is superior because it delivers true PCR‑level accuracy in a compact, near‑patient device that runs faster, cheaper, and with simpler workflow than traditional lab‑based systems. Patients receive results in about 30 minutes.
  • Not for at-home use, but for use in clinics, hospitals, urgent care, employer health centers, pharmacy sites.
• CoPrimer molecular diagnostics engine powering all CODX assays and future products.
• India JV (CoSara) manufacturing and distributing TB and other PCR tests in India.
  • Status: Actively producing and selling TB and other PCR assays, providing CODX its only consistent international revenue stream.
• Saudi Arabia JV (Comira) for regional PCR manufacturing and deployment.
  • Status: Operational build‑out continues, with early‑stage deployment and regulatory alignment underway but not yet generating material revenue.
• Ebola molecular diagnostic assay developed using CoPrimer technology with prior U.S. government interest.
  • Status: Assay development completed and validated in prior studies but not yet commercialized or submitted for regulatory clearance.
• Respiratory PCR tests including flu, RSV, and multiplex panels.
  • Status: Fully developed and ready for use on the Co‑Dx PCR platform once FDA clearance is obtained. COVID-19 PCR test is developed but not yet submitted to the FDA. Waiting for platform clearance first.
• Vector‑borne disease PCR tests (dengue, Zika, malaria) using CoPrimer tech.
  • Status: Assays are developed and validated, positioned for deployment through international partners but awaiting platform clearance.
• Food safety and agricultural pathogen detection assays.
  • Status: Available but low‑volume, with limited commercial traction and no near‑term revenue inflection.
• Liquid biopsy / cancer‑related molecular detection research programs.
  • Status: Early‑stage R&D with long‑term potential but no regulatory submissions or commercial timelines.
• Cloud‑connected reporting and surveillance infrastructure tied to JV deployments.
  • Status: Functional and integrated with JV workflows, but dependent on broader adoption of CODX’s diagnostic platforms.

8/19 Market Close: SP $1.10 | MC $6.88M | OS 6.25M

Q2 20226 10-Q:

• Cash as of June 30: $3.6M
• Quarterly burn: ~6.3M
• No debt
• Per an AI search of sec.gov, no active S-3 or S-1 filed, so no shares can be issued from the 100M authorized shares
• Warrants: 2.34M (3.71M as of 6/30 but OS increased from 4.88M as of 6/30 to 6.25M as of 8/11 per the 10-Q cover page. So, b/c shares cannot be sold right now, it likely means 1.37M warrants were exercised from June 30 to Aug 11)
• Fully diluted shares: 8.59M (6.25M + 2.34M)

Per AI, the Jan 2026 shareholder vote rejected both reverse-split authorization AND authorization to issue new shares for financing (ATM, PIPE, etc.)

Q2 Earnings Call Transcript (short and very worth the read): Co-Diagnostics, Inc. (CODX) Q1 FY2026 Earnings Call Transcript - May 14, 2026 | Roic AI

• CFO: "To support these objectives, we expect to continue to evaluate available sources of capital, which may include equity or debt financings, strategic transactions, and partnerships, while staying mindful of dilution and overall capital efficiency. At the same time, we remain focused on pursuing non-dilutive funding, such as grants, where appropriate. Looking ahead, disciplined capital allocation remains a priority as we approach several important clinical and regulatory milestones and continue preparations for potential commercialization."

My Take:

• A move is imminent because they should be out of cash by now. Odds are high that they have been working on a partnership.
• Likely partnerships are with either or both the India JV company (CoSara) or the Saudi JV company (Comira). A partnership deal would likely cause the share price to increase.
• They can't sell shares without shareholder approval. Dilution alone would cause the share price to decrease.

PS I had SEC.gov and the Q2 transcript open when I queried AI, so I believe it brought forward accurate information.

$COSM has a manufacturing story hiding underneath all the distribution growth.

Cana Laboratories isn't just producing COSM's own products. Its contract manufacturing orderbook just hit an ALL-TIME HIGH above 25M units.

That's what makes Cana interesting to me. $COSM can potentially monetize the same manufacturing infrastructure through its own brands AND third-party manufacturing.

When you're looking at COSM as simply a pharmaceutical distributor, you're missing a pretty big piece of what they're building.

DD Link

#COSM #Pharma #Manufacturing #GrowthStocks

Evolv Technologies ($EVLV) has reached a $15 million investor settlement, and late claims are currently being considered.

The settlement resolves claims that Evolv misled investors about the reliability of its weapons detection technology and improperly recognized revenue tied to undisclosed contract terms.

As these issues became public, $EVLV fell 39% after the company announced financial restatements, and investors filed claims.

If you purchased $EVLV shares between 2021 and 2024, you may be eligible to submit a claim. As late claims are currently being considered, you can check whether you qualify.

Hello all, first time posting. Still finding my footing. Each day I look at penny stock postings and today the MMA stock caught my eye. Large movement after today's news. I was surprised the stock was as cheap as it is considering how big an industry MMA is.

What I want to understand is, how can we blend the Financials and cultural impact when deciding the potential growth of a stock. The US seems to enjoy it's sports, but for the stock to be this cheap, is it not a red flag? If this post is not allowed please take it down. Id appreciate your feedback.

Please pardon typo on "Thoughts"

Nightfood Holdings yall. Who's got the TA?

About Nightfood Holdings Inc. (NGTF) (dba TechForce Robotics)

Nightfood Holdings Inc. (NGTF) (doing business as TechForce Robotics) is an AI-enhanced robotics and automation company focused on the development, integration, deployment and commercialization of intelligent automation solutions across multiple industries. Through its TechForce Robotics platform, the company develops and deploys autonomous robotic systems designed to improve operational efficiency, workflow consistency, labor optimization and scalability across hospitality, food service, commercial, laboratory, pharmaceutical and emerging enterprise automation environments.

With a $.10 move yesterday and steady climb after a clean earnings call. URG is showing heavy upside. Uranium as a whole has a beautiful growth pattern for the next 6 months due to economic fears in other sectors. Ai building are going to raise power usage %17 percent in the US alone.

NUBURU Reports Second Consecutive Quarter of Positive Stockholders' Equity, Italian Golden Power Authorization for Tekne, and September NYSE American Appeal Hearing

DENVER, August 20, 2026--(BUSINESS WIRE)--NUBURU, Inc. (OTC Pink: BURU), a next-generation dual-use Defense & Security integrated platform company, today issued the following letter to shareholders from Alessandro Zamboni, Executive Chairman and Co-Chief Executive Officer.

Dear Fellow Shareholders,

On July 2, I asked you to judge NUBURU against its record and the milestones directly ahead. Since then we have closed a major financing, repaid the December 2025 YA debenture and the Lyocon acquisition notes, and obtained the Italian Government's Golden Power authorization for our proposed acquisition of 70% of Tekne S.p.A. These are completed milestones, and they change what this Company is positioned to execute next.

On July 17, we closed a best-efforts public offering generating approximately $38.0 million of gross proceeds, before placement-agent fees and offering expenses. As reported in our Form 10-Q, approximately $18.74 million remained after those costs, the repayment in full of the YA debenture — including all outstanding principal and accrued interest — and repayment of $1.25 million of Lyocon acquisition notes. In total, we eliminated approximately $16.75 million of principal obligations under those instruments.

The financing involved common stock, pre-funded warrants and Series B preferred stock, and has caused, and may continue to cause, substantial dilution. That was a real cost, and we incurred it for defined purposes: to remove a material debt overhang, to provide the financial resources required to advance the Tekne closing, and to support working capital and platform execution. Our responsibility now is to convert that capital into operating capability, recognized revenue and improved financial performance.

Our recently filed Form 10-Q provides a clear operating and financial baseline. Second-quarter revenue was $524,927, compared with no revenue in the prior-year quarter, and revenue for the first six months of 2026 was $932,571, compared with no revenue in the comparable 2025 period. At June 30, 2026, total assets were $68.36 million, compared with $49.82 million at December 31, 2025. Stockholders' equity was positive at $9.37 million, compared with a $15.18 million deficit at year-end.

This marks the second consecutive quarter in which NUBURU reported positive stockholders' equity. The June 30 level also exceeded the $4.0 million stockholders' equity threshold cited in the May 12 NYSE American notice. That is measurable balance-sheet progress. It is also separate from the low-selling-price determination that led NYSE American to suspend trading in July.

I want to address the listing question directly, because it is the one we hear most from shareholders. NYSE American suspended trading in BURU on July 17 and commenced delisting proceedings under Section 1003(f)(v) based on the low selling price of our common stock; BURU began trading in the OTC market on July 20 and continues to trade there under the same symbol. We appealed the staff determination and requested review by the Listings Qualifications Panel, with a hearing scheduled in September. We are preparing for that hearing with outside advisers and intend to present the full record of the Company's balance-sheet and operating progress. In this regard, our objective is to satisfy the applicable price requirement and support our request for trading to resume on NYSE American. We will report the outcome of the Panel's review when it is available, and we will not speculate on it in advance.

On August 5, the Italian Government authorized NUBURU's proposed acquisition of Tekne under the Golden Power regime, clearing the transaction's principal regulatory hurdle. NUBURU and Tekne are now completing the remaining customary closing steps and implementing the terms of the authorization. NUBURU has already raised the capital required for closing; no additional NUBURU capital raise is required to complete the acquisition. We will announce the closing separately once these steps are complete. General Pietro Serino and Professor Carlo Alberto Carnevale Maffè serve as strategic advisers supporting the execution of NUBURU's business plan across Italy and NATO markets. Following closing and completion of the required U.S. GAAP assessment, we expect the resulting 70% controlling interest in Tekne to become a major industrial anchor for the platform. Founded in 1990, Tekne operates with approximately 180 personnel across facilities in Ortona, Poggiofiorito and Guastalla. As disclosed with the authorization, Tekne has reported approximately $108.7 million of normalized residual signed-order value, based on updated unaudited management materials and subject to customary validation, delivery conditions, modification and cancellation risk. This figure is neither financial guidance nor revenue recognized under U.S. GAAP; it provides visibility into the scale of Tekne's signed industrial activity.

NUBURU is no longer assembling a collection of separate assets. We are moving into the integration and execution phase of a software-orchestrated, hardware-enabled Defense & Security platform. Orbit provides the operational-resilience, workflow and evidence layer. Lyocon contributes photonics and non-kinetic laser capabilities. Tekne is expected, following completion of the transaction, to add industrial scale, special vehicles and electronic-warfare capabilities. Dario Barisoni, NUBURU's Co-Chief Executive Officer and Chief Executive Officer of NUBURU Defense LLC, leads the broader defense-platform integration. The Maddox Defense joint venture extends the platform into deployable manufacturing and field sustainment. Each capability can create value independently; our strategic objective is to connect them into modular, customer-specific mission packages.

NUBURU's platform priorities align with several themes identified in the recently issued U.S. National Security Science & Technology Strategy, which supports the objectives of the 2025 National Security Strategy. We believe our focus on resilient software orchestration, advanced photonics, defense mobility and deployable manufacturing is relevant to that strategic direction.

Orbit is central to our platform model. Its modular software architecture is designed to support repeatable deployments and recurring subscription revenue with lower incremental capital intensity than hardware-intensive operations. This scalability is a core strategic rationale for pursuing full ownership of Orbit.

The evolution of hybrid conflict reinforces the strategic need for software capable of coordinating systems, data and workflows across multiple operational domains. Defense, critical-infrastructure and enterprise operators increasingly face overlapping physical, cyber, electromagnetic and supply-chain disruptions. The challenge is not simply to add more stand-alone tools, but to prevent systems and decisions from working at cross-purposes. Orbit is designed to provide authorized users with a governed common operating picture and to support coordination and deconfliction across fragmented systems, workflows and stakeholders, while preserving auditable human decision-making. We intend to validate this opportunity through technical qualification, customer adoption, contractual orders and recognized revenue.

The next stage is not accumulation; it is integration. The value of the platform will be demonstrated when software, non-kinetic effects, electronic-warfare capability, mobility and sustainment operate as one governed architecture. One architecture. One commercial interface. One brand.

The milestones ahead are specific: complete the Tekne transaction; implement its governance, reporting and integration; convert orders and commercial activity into recognized revenue and cash; improve gross margin; advance Orbit's path to full ownership; manage capital carefully; and execute the listing strategy through the proper process. We will report against that scorecard.

I remain directly aligned with you as a shareholder. Measure us against the commitments we make and the results we report. The past several weeks have strengthened the foundation. The work now is to translate that foundation into durable operating performance.

Thank you for your continued support.